Treatment of MOLM-14 cells and newly diagnosed and relapsed FLT3-ITD-mutated AML patient–derived cells with quizartinib and azacitidine/decitabine resulted in synergistic growth inhibition. Here, FLT3 is linked to acute myeloid leukemia.